Elevai Labs (ELAB) said Thursday that its Elevai Biosciences subsidiary filed two patent applications for its lead candidate, EL-22, to treat muscle loss in obese patients.
The applications cover both standalone and combination therapies with GLP-1 receptor agonists, according to the company.
A phase 1 study of EL-22 in South Korea has been completed, showing safety and tolerability in healthy volunteers, Elevai said, adding it plans to evaluate the investigational drug's efficacy in combination with GLP-1 to counteract muscle wasting associated with the medications while promoting weight loss.
Shares of the drug developer rose more than 30% in recent premarket activity.
Price: 0.1109, Change: +0.03, Percent Change: +30.16
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。